CEOP-21 Versus CEOP-14 Chemotherapy with or Without Rituximab for the First-Line Treatment of Patients with Aggressive Lymphomas: Results of the HE22A99 Trial of the Hellenic Cooperative Oncology Group.
The cancer journal（2007）
关键词
aggressive non-Hodgkin lymphotna,CEOP,dose-intensification,rituximab,overall survival
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要